HDAC9 and breast cancer: One recent phase III trial reported that HDAC inhibitors exemestane and entinostat did not improve survival in patients with aromatase inhibitor-resistant advanced BC although pharmacodynamic analysis confirmed target inhibition of HDACi (44).